New Tactic In ANDA Litigation: Novo Blocks Generic Prandin By Changing Its Patent Use Code
Executive Summary
Novo Nordisk succeeded in an unusual maneuver in blocking Caraco Pharmaceutical from getting a generic version of its blood glucose-lowering drug Prandin (repaglinide) on the market. It changed the use code on the patent covering the drug in combination with metformin so that Caraco could not get approval for a monotherapy
You may also be interested in...
Patent Use Codes For Brands Can Be Challenged By Generics, Supreme Court Rules
The high court says the Hatch-Waxman Act did not intend for one patented use of a drug to prevent the marketing of a generic for unpatented uses; Justice Sotomayor criticizes FDA for not providing clearer direction to brand manufacturers about what to include in their use codes.
Patent Use Codes: Will Supreme Court Curb Carve-outs Or Spawn Suits?
The high court hears oral arguments in a case that could limit the ability of generics to carve out still-patented uses from their labeling to get prompt ANDA approval. Brand manufacturers argue that allowing such challenges will invite a flood of lawsuits. Caraco v. Novo revolves around a patent use code for the diabetes drug Prandin.
Patent Use Code Arguments At Supreme Court Focus On Role Of FDA In Prandin Patent Dispute
In oral arguments in Caraco v. Novo Nordisk, justices also ask whether Caraco could have sued FDA for accepting Novo’s Prandin patent use code instead of filing a counterclaim against Novo to force it to change the code.